Introduction {#sec1-1}
============

One of the most unpleasant adverse events caused by anticancer therapy is alopecia, with an incidence of 70%.\[[@ref1]\] Chemotherapy induces a rapid breakdown of mitotic activity, which interrupts the normal anagen growth of hair follicles and can lead to partial or complete scalp hair loss about 2 weeks after the beginning of treatment.\[[@ref2]\] Chemotherapy-induced alopecia (CIA) is often temporary as hair usually starts to regrow within 3--4 weeks after the last treatment; however, changes in hair characteristics are often reported.\[[@ref3]\]

The amount of hair loss is dependent on the type of cytotoxic drugs and secondarily on the cytotoxic sensitivity of each patient.\[[@ref4]\] Higher dosages of chemotherapy lead to more severe alopecia, as well as combination chemotherapy with several agents.\[[@ref5]\] Severe hair loss is associated with standard chemotherapy regimens containing doxorubicin, paclitaxel, docetaxel, cyclophosphamide, and/or epirubicin.\[[@ref6][@ref7]\]

CIA significantly affects the quality of life of many cancer patients regardless of gender or age.\[[@ref8][@ref9]\] The suffering associated with CIA is, however, mostly described among women with breast cancer.\[[@ref10]\] To avoid this traumatic event, patients may decide to refuse chemotherapy or choose a less effective treatment.\[[@ref11]\]

Since 1970, scalp cooling (SC) or cryotherapy has proved to be the most effective and widely used method to prevent CIA.\[[@ref12][@ref13][@ref14]\] SC works by lowering the scalp skin temperature, which reduces the exposure and metabolism of cytotoxic agents to the hair follicle.\[[@ref15]\] Although a scalp skin temperature below 18°C seems to produce better results, there is currently no indication for a cutoff point under which alopecia can be completely prevented.\[[@ref16]\] Therefore, it is crucial to optimize the reduction of the scalp skin temperature by ensuring a tight contact between the cold cap and the skin of the scalp.\[[@ref17]\] The efficacy of SC has been increasingly demonstrated over the past 20 years, with average success rates varying from 50% to 70%.\[[@ref18][@ref19][@ref20]\] The best results in terms of hair preservation have been reported for taxane-based chemotherapy;\[[@ref21][@ref22]\] the results for taxane-based chemotherapy are better than those for anthracycline-based chemotherapy.\[[@ref23][@ref24]\] However, two separate meta-analyses have confirmed that there is a clinical evidence to recommend SC to CIA prevention in breast cancer patients using doxorubicin, epirubicin, or taxane-containing chemotherapy regimens.\[[@ref25][@ref26]\] Patient baseline characteristics that could affect the efficacy of SC efficacy have not been extensively investigated.\[[@ref27][@ref28]\]

Recently, two SC devices have been approved by the US Food and Drug Administration based on the positive results of prospective studies.\[[@ref29][@ref30]\] Among these, the Paxman cooling device\[[@ref31]\] was evaluated in the unblinded Scalp Cooling Alopecia Prevention Randomized Controlled Phase 3 trial including 142 women with Stage I and II breast cancer undergoing chemotherapy. Analysis showed that 50.5% of patients in the SC group had hair preservation, compared to no patients in the control group. Hair preservation was greater among patients who received taxane-based chemotherapy compared to those who received an anthracycline-based regimen (59% vs. 16%). SC is considered a reasonable, supportive care option as it is well tolerated by cancer patients.\[[@ref32]\] Moderate headaches, coldness, and/or uncomfortable sensations are the most frequent side events related to SC.\[[@ref33]\] Scalp metastases are not associated with SC during chemotherapy, but caution is recommended for its broad-scale application.\[[@ref34]\] Despite evidence of its efficacy and safety, there are several practical concerns to make SC available for routine use, including the device cost and the impact on patient flow and hospital logistics.\[[@ref35]\] Hence, we report a multicenter observational study aiming to evaluate the Paxman scalp cooler in preventing CIA among women with breast cancer in daily oncological practice.

Methods {#sec1-2}
=======

We conducted a prospective observational study in three oncology centers located in Northern Italy with the current experience (at least 30 patients treated within 12 months) in using the Orbis Paxman Hair Loss Prevention System. The study protocol was approved by the Ethical Committee at each site, and all patients provided signed informed consent. The devices were obtained owing to philanthropic funding. We included women with early breast cancer undergoing SC during anthracycline- and/or taxane-based chemotherapy with curative intent from January 2014 to December 2016. The following chemotherapeutic regimens were administered: doxorubicin (60 mg/mq) in combination with cyclophosphamide (600 mg/mq) (AC); AC followed by paclitaxel (80 mg/mq); epirubicin (90 mg/mq) in combination with cyclophosphamide (600 mg/mq) (EC); 5-fluorouracil (500 mg/mq); epirubicin (75--90--100 mg/mq); cyclophosphamide (600 mg/mq) (FEC); FEC followed by docetaxel (100 mg/mq); paclitaxel (80 mg/mq) alone; and docetaxel alone (100 mg/mq). The chemotherapy schedules were based on the National Comprehensive Cancer Network Guidelines.\[[@ref36]\] The exclusion criteria were as follows: age \<18 years, metastatic disease, blood disorders including but not limited to cryoglobulinemia, and cold agglutinin disease. SC to prevent hair loss was offered as supportive care to all eligible breast cancer patients by an oncologist during the initial consultation about chemotherapy. The nursing team informed patients who decided to use SC about the procedure, the anticipated effect, and the potential adverse events. Patients declining SC did so from their own choice, and the incidence of CIA in this group was not documented. The cool cap was applied during each chemotherapy cycle by a nurse according to the device manual. The device cools the skin on the patient\'s scalp to approximately 18°C by circulating coolant throughout a cap at --4°C. SC began 30 min before chemotherapy infusion; the postinfusion cooling time after the last drug was 60 min for all regimens except for 150 min for the AC regimen. The patient\'s hair was dampened before putting the cap in place to minimize isolation of the air layer between the cap and the scalp skin. To prevent patients from suffering coldness, the forehead was protected with a thin cotton layer and a blanket was provided. Mild headaches were treated with paracetamol, if requested by the patient. Hair loss was rated according to the Common Terminology Criteria for Adverse Event Version 4.0 as follows: Grade 0 (G0), no hair loss; Grade 1 (G1), \<50% hair loss not requiring a wig or head cover; and Grade 2 (G2), ≥50% hair loss. Success was defined as G0--G1 hair loss. Patients who agreed to receive SC were assessed for hair loss at baseline and before each cycle of chemotherapy by a nurse who also considered the patient\'s opinion.\[[@ref37]\] Patients with hair loss of G2 after the second cycle of chemotherapy did not continue SC. The reasons for SC discontinuation and the related side effects were also documented. Nurses also recorded baseline patient characteristics and the chemotherapy regimen in the electronic study database. The data were then analyzed by descriptive statistics using Microsoft Excel.
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=======

A total of 220 women with breast cancer were included in the study. The baseline patient characteristics and clinical information are summarized in [Table 1](#T1){ref-type="table"}. The median age was 49 years; almost all patients had a South European ethnicity and none had alopecia at the baseline. In total, 44% (*n* = 98) of the participants received anthracycline-based chemotherapy, 30% (*n* = 64) were administered anthracycline followed by taxane chemotherapy, and 26% (*n* = 58) received taxane-based chemotherapy. A median of eight sessions was performed with the Paxman scalp cooler.

###### 

Demographic information and baseline characteristics

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                                                                                               Participants (*n*=220) No. (%)
  ----------------------------------------------------------------------------------------------------------------------- --------------------------------
  Age (years)                                                                                                             

   Median (range)                                                                                                         49 (34-66)

  Ethnic background                                                                                                       

   West and South European                                                                                                215 (98)

   African                                                                                                                2 (1)

   Asian                                                                                                                  3 (1)

  CTCAE\* V4.0 Alopecia Grade 0 at baseline\                                                                              212 (96) 8 (4)
  CTCAE\* V4.0 Alopecia Grade 1 at baseline                                                                               

  Study site                                                                                                              

   1                                                                                                                      150 (68)

   2                                                                                                                      40 (18)

   3                                                                                                                      30 (14)

  Planned chemotherapy regimen                                                                                            

   AC: doxorubicin, 60 mg/mq and cyclophosphamide, 600 mg/mq (4 cycles every 3 weeks)                                     59 (27)

   AC followed by paclitaxel, 80 mg/mq weekly for 4 cycles                                                                22 (10)

   EC: epirubicin, 90 mg/mq and cyclophosphamide, 600 mg/mq (4 cycles every 3 weeks)                                      20 (9)

   EC followed by paclitaxel, 80 mg/mq weekly for 4 cycles                                                                11 (6)

   FEC: 5-fluorouracil, 500 mg/mq, epirubicin, 75-90-100 mg/mq and cyclophosphamide, 500 mg/mq (4 cycles every 3 weeks)   19 (8)

   FEC 3-4 cycles followed by docetaxel, 100 mg/mq (3 cycles every 3 weeks)                                               31 (14)

   DC: docetaxel, 75 mg/mq with cyclophosphamide, 600 mg/mq (4-6 cycles every 3 weeks)                                    21 (9)

   Paclitaxel, 80 mg/mq weekly for 4 cycles                                                                               28 (13)

   Docetaxel, 100 mg/mq weekly for 3 cycles                                                                               9 (4)

  Scalp cooling sessions                                                                                                  

   Median (range)                                                                                                         8 (1-16)
  --------------------------------------------------------------------------------------------------------------------------------------------------------

\*CTCAE: Common Terminology Criteria for Adverse Events

Two hundred patients were available for success rate evaluation. Twenty patients interrupted SC immediately during the first cycle of chemotherapy for reasons other than CIA and were recorded as discontinued \[[Table 2](#T2){ref-type="table"}\]. Four patients felt that too much time was required and 16 patients interrupted SC for moderate-to-severe cooling-related adverse events, including migraine (*n* = 8), coldness (*n* = 4), dizziness (*n* = 2), and vomiting (*n* = 2).

###### 

Patient disposition

                                                 Participants No. (%)
  ---------------------------------------------- ----------------------
  Included in the study                          220 (100)
  Analyzed for effectiveness                     200 (91)
  Discontinued for other reasons than alopecia   20 (9)
   Low tolerability                              4
   Side effects                                  16

As shown in [Table 3](#T3){ref-type="table"}, at the end of their planned chemotherapy regimens, 136 patients reported hair loss of G0--G1. Thus, the overall success rate was 68%. The remaining 64 (32%) patients experienced G2 hair loss within the first two cycles of chemotherapy, and the treatment was considered to have failed in these patients. Hair preservation according to the type of cytotoxic agent is shown in [Table 4](#T4){ref-type="table"}. The best results were reported for 49 (89%) of 55 patients receiving taxane-based chemotherapy. Prevention of hair loss was achieved in 47 (78%) of 60 patients undergoing treatment with both anthracyclines (mainly epirubicin based) and taxanes in a sequential scheme. Finally, 88 patients received an anthracycline-based chemotherapy regimen, of whom 40 (47%) were able to preserve their hair. After a median follow-up of 24 months (range: 16--34 months) following the last treatment with SC, none of the patients had developed scalp skin metastases and nine patients had breast cancer recurrence.

###### 

Scalp cooling success rate

  Parameter   Participants No. (%)
  ----------- ----------------------
  Success     136 (68)
  Failure     64 (32)
  Total       200 (100)

###### 

Scalp cooling success rate according to chemotherapy regimen

  Parameter   Participants No. (%)   Anthracycline-Taxane\*\*\*   
  ----------- ---------------------- ---------------------------- ----------
  Success     40 (47)                49 (89)                      47 (78)
  Failure     45 (53)                6 (11)                       13 (22)
  Total       85 (100)               55 (100)                     60 (100)

\*AC, EC , FEC, DC. \*\*Paclitaxel, docetaxel. \*\*\*AC followed paclitaxel, FEC followed docetaxel, EF followed by docetaxel

Discussion {#sec1-4}
==========

Our results confirm that SC applied in routine clinical practice can avoid CIA among women with breast cancer undergoing curative chemotherapy with taxane and/or anthracycline cytostatic agents. In our study, the Paxman device had been implemented for at least 1 year; therefore, the nursing team had sufficient experience with the SC procedure. This could partially explain the high overall success rate of 68%, which is comparable to those in similar recent studies.\[[@ref29][@ref38]\]

We conducted a multicenter prospective study enrolling 220 early-stage breast cancer patients treated with specific chemotherapy regimens to standardize the study results.

Taxane-induced severe alopecia occurs in 70%--80% of patients at the commonly used dosages.\[[@ref7]\] Our observation of an 89% success rate in the group of patients receiving taxane-based therapy clearly shows the added value of SC.

We also add evidence to the role of SC in patients receiving both anthracycline- and taxane-based chemotherapy (78% success) as was also reported by Friedrichs and Carstensen.\[[@ref23]\]

For anthracycline-based treatment, generally inferior results are reported.\[[@ref26]\] In our study, patients receiving FEC or EC achieved better results in terms of hair preservation compared to those receiving AC regimen. Although subgroup analysis was not conducted due to the limited number of patients, women receiving epirubicin at lower dose experienced less hair loss (data not shown), concordant with the findings of another report.\[[@ref39]\]

In our experience, the duration of SC did not seem to affect its success rate.\[[@ref27]\] Only 47% of the patients receiving AC did not show alopecia, although the postinfusion cooling time was longest for AC regimen compared to those for the other chemotherapy regimens. SC was confirmed to be a safe procedure for breast cancer patients as no scalp metastases were detected throughout the entire study period, and the percentage of disease recurrence in 2 years of follow-up was in line with current evidence.\[[@ref40]\] Finally, we found no indication that breast cancer patients undergoing chemotherapy with SC with no alopecia were less sensitive to chemotherapy and, therefore, at risk of a worse outcome prognosis, as suggested elsewhere;\[[@ref41]\] however, long-term follow-up is still ongoing. The present study had several limitations. First, we used a cohort study design without randomization; to standardize the study results, we investigated specific chemotherapy regimens known to cause alopecia in women with early-stage breast cancer.

Alopecia assessment was performed by the nurse together with the patient using a rating scale for better objectively; however, hair preservation by SC is considered relevant if evaluated by patients themselves.\[[@ref37]\]

Finally, our results were obtained from comparable cancer sites in terms of workload and logistical organization, and this could explain the high success rate, including but not limited to the prevalence of taxane-based chemotherapy regimen. Despite these limitations, our results indicate that SC should be offered as a part of supportive care to cancer patients.\[[@ref42]\] As reported by Shaw *et al*., nursing and medical staff commitment are fundamental to the implementation of SC in the daily practice of oncology units.\[[@ref43]\]

In our study, only 10% of the participants prematurely dropped out for reasons other than CIA. The key factors to keep patients on the intervention included good management of the device by the nursing team as well as a dedicated nurse during the first session of SC to provide support and motivation to bear the mild-related adverse events and discomfort. The present study did not perform a cost evaluation, which might be included in a future study.

Conclusion {#sec1-5}
==========

Our study confirmed that SC provides a reliable chance for breast cancer patients to keep their hair during taxane- and/or anthracycline-based chemotherapy, especially when epirubicin and taxanes are administered.

Since 2017, we are routinely offering SC to newly diagnosed breast cancer patients undergoing chemotherapy.

The use of SC device requires extra time and effort on the part of the nursing team; therefore, it would be important to investigate patient- and treatment-related variables that might influence the efficacy of SC.
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